false Q3 --03-31 2024 0001672571 0001672571 2023-04-01 2023-12-31 0001672571 2024-02-14 0001672571 2023-12-31 0001672571 2023-03-31 0001672571 us-gaap:NonrelatedPartyMember 2023-12-31 0001672571 us-gaap:NonrelatedPartyMember 2023-03-31 0001672571 ACHN:CustomerMember 2023-12-31 0001672571 ACHN:CustomerMember 2023-03-31 0001672571 2023-10-01 2023-12-31 0001672571 2022-10-01 2022-12-31 0001672571 2022-04-01 2022-12-31 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-03-31 0001672571 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001672571 ACHN:StatutoryReserveMember 2023-03-31 0001672571 us-gaap:RetainedEarningsMember 2023-03-31 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-06-30 0001672571 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001672571 ACHN:StatutoryReserveMember 2023-06-30 0001672571 us-gaap:RetainedEarningsMember 2023-06-30 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001672571 2023-06-30 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-09-30 0001672571 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001672571 ACHN:StatutoryReserveMember 2023-09-30 0001672571 us-gaap:RetainedEarningsMember 2023-09-30 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001672571 2023-09-30 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-03-31 0001672571 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001672571 ACHN:StatutoryReserveMember 2022-03-31 0001672571 us-gaap:RetainedEarningsMember 2022-03-31 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001672571 2022-03-31 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-06-30 0001672571 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001672571 ACHN:StatutoryReserveMember 2022-06-30 0001672571 us-gaap:RetainedEarningsMember 2022-06-30 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001672571 2022-06-30 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-09-30 0001672571 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001672571 ACHN:StatutoryReserveMember 2022-09-30 0001672571 us-gaap:RetainedEarningsMember 2022-09-30 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001672571 2022-09-30 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-04-01 2023-06-30 0001672571 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001672571 ACHN:StatutoryReserveMember 2023-04-01 2023-06-30 0001672571 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001672571 2023-04-01 2023-06-30 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-07-01 2023-09-30 0001672571 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001672571 ACHN:StatutoryReserveMember 2023-07-01 2023-09-30 0001672571 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001672571 2023-07-01 2023-09-30 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-10-01 2023-12-31 0001672571 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0001672571 ACHN:StatutoryReserveMember 2023-10-01 2023-12-31 0001672571 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-10-01 2023-12-31 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-04-01 2022-06-30 0001672571 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001672571 ACHN:StatutoryReserveMember 2022-04-01 2022-06-30 0001672571 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001672571 2022-04-01 2022-06-30 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-07-01 2022-09-30 0001672571 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001672571 ACHN:StatutoryReserveMember 2022-07-01 2022-09-30 0001672571 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001672571 2022-07-01 2022-09-30 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-10-01 2022-12-31 0001672571 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001672571 ACHN:StatutoryReserveMember 2022-10-01 2022-12-31 0001672571 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-10-01 2022-12-31 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-12-31 0001672571 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001672571 ACHN:StatutoryReserveMember 2023-12-31 0001672571 us-gaap:RetainedEarningsMember 2023-12-31 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-12-31 0001672571 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001672571 ACHN:StatutoryReserveMember 2022-12-31 0001672571 us-gaap:RetainedEarningsMember 2022-12-31 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001672571 2022-12-31 0001672571 ACHN:StockPurchaseAgreementMember ACHN:Dazhong368IncMember 2019-06-29 2019-07-01 0001672571 ACHN:Dazhong368IncMember ACHN:StockPurchaseAgreementMember 2019-07-01 0001672571 ACHN:MRBarryWanMember ACHN:StockPurchaseAgreementMember 2023-04-09 2023-04-10 0001672571 ACHN:MRBarryWanMember ACHN:StockPurchaseAgreementMember 2023-04-10 0001672571 ACHN:PeriodEndRMBMember 2023-12-31 0001672571 ACHN:PeriodEndPeriodAverageRMBMember 2023-12-31 0001672571 ACHN:PeriodEndRMBMember 2023-03-31 0001672571 ACHN:PeriodEndPeriodAverageRMBMember 2023-03-31 0001672571 ACHN:PeriodEndRMBMember 2022-12-31 0001672571 ACHN:PeriodEndPeriodAverageRMBMember 2022-12-31 0001672571 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001672571 us-gaap:LeaseholdImprovementsMember 2022-03-31 0001672571 us-gaap:OfficeEquipmentMember 2023-12-31 0001672571 us-gaap:OfficeEquipmentMember 2022-03-31 0001672571 srt:PresidentMember 2019-08-01 2019-08-31 0001672571 srt:PresidentMember 2021-04-01 2022-03-31 0001672571 srt:PresidentMember 2021-05-01 2021-05-31 0001672571 srt:PresidentMember 2022-12-28 2022-12-29 0001672571 srt:PresidentMember 2022-04-01 2023-03-31 0001672571 us-gaap:RelatedPartyMember 2023-04-10 2023-04-10 0001672571 ACHN:MrWanMember 2023-04-01 2023-12-31 0001672571 us-gaap:RelatedPartyMember 2023-12-31 0001672571 us-gaap:RelatedPartyMember 2023-03-31 0001672571 2008-01-01 2008-01-01 0001672571 country:US 2023-04-01 2023-12-31 0001672571 country:US 2022-04-01 2022-12-31 0001672571 country:HK 2023-04-01 2023-12-31 0001672571 country:HK 2022-04-01 2022-12-31 0001672571 country:CN 2023-04-01 2023-12-31 0001672571 country:CN 2022-04-01 2022-12-31 0001672571 us-gaap:CommonClassAMember 2023-12-31 0001672571 us-gaap:CommonClassAMember 2019-08-19 0001672571 us-gaap:CommonClassAMember 2021-10-11 0001672571 us-gaap:PreferredStockMember 2021-10-11 0001672571 2023-03-28 0001672571 srt:PresidentMember 2023-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ______

Commission File Number 000-56157

Antiaging Quantum Living Inc.

(Exact name of registrant as specified in its charter)

New York		47-2643986
(State or Other Jurisdiction		(I.R.S. Employer
of Incorporation or Organization)		Identification No.)

133-27 39th Ave Ths #PH2A

Flushing, NY 11354

(Address of Principal Executive Offices) (Zip Code)

(929) 527-5382

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Not Applicable		Not Applicable		Not Applicable

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of February 14, 2024 , the registrant had 29,995,000 shares of Class A common stock outstanding.

TABLE OF CONTENTS

		PAGE

	Note about Forward-Looking Statements	3

	PART I - FINANCIAL INFORMATION
Item 1	Financial Statements	4
	Balance Sheets as of December 31, 2023 (unaudited) and March 31, 2023	5
	Statements of Operations for the three and nine months ended December 31, 2023 and 2022 (unaudited)	6
	Statements of Changes in Stockholders’ Deficit for the nine months ended December 31, 2023 and 2022 (unaudited)	7
	Statements of Cash Flows for the nine months ended December 31, 2023 and 2022 (unaudited)	8
	Notes to Unaudited Financial Statements	9
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operation	19
Item 3	Quantitative and Qualitative Disclosures About Market Risk	21
Item 4	Controls and Procedures	21

	PART II - OTHER INFORMATION

Item 1	Legal Proceedings	22
Item 1A	Risk Factors	22
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	22
Item 3	Defaults Upon Senior Securities	22
Item 4	Mine Safety Disclosures	22
Item 5	Other Information	22
Item 6	Exhibits	23

SIGNATURES		24

NOTE ABOUT FORWARD-LOOKING STATEMENTS

Except for historical information, this quarterly report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this quarterly report on Form 10-Q other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this quarterly report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

Unless expressly indicated or the context requires otherwise, the terms “Antiaging,” “company,” “we,” “us,” and “our” in this document refer to Antiaging Quantum Living Inc, a New York corporation.

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

INDEX TO FINANCIAL STATEMENTS

Consolidated Balance Sheets as of December 31, 2023 (unaudited) and March 31, 2023	5

Consolidated Statements of Operations for the three and nine months ended December 31, 2023 and 2022 (unaudited)	6

Consolidated Statements of Changes in Stockholders’ Deficit for the nine months ended December 31, 2023 and 2022 (unaudited)	7

Consolidated Statements of Cash Flows for the nine months ended December 31, 2023 and 2022 (unaudited)	8

Notes to Unaudited Consolidated Financial Statements	9 - 18

ANTIAGING QUANTUM LIVING INC (FKA. ACHISON INC)

CONSOLIDATED BALANCE SHEETS

	December 31,			March 31,
	2023			2023
	(Unaudited)
ASSETS
Current Assets
Cash and cash equivalents	$	125,648		$	354
Advances to suppliers		27,554			-
Prepaid expenses and other current assets		30,096			-
Total Current Assets		183,298			354
Property, plant and equipment, net		155,277			540
Other non-current assets		33,127			-
Operating lease right of use asset, net		627,389			-
Total Non-Current Assets		815,793			540
Total Assets		999,091			894

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities
Accounts payable and accrued expenses		18,996			901
Other payables		3,007			-
Loan from shareholders		371,369			83,300
Other current liabilities		11,107			-
Advances from customers		4,345			-
Contract liabilities		-			2,800
Operating lease liabilities - current		317,333			-
Total Current Liabilities		726,157			87,001
Long-term loan payables		427,675			-
Total Non-Current Liabilities		427,675			-
Total Liabilities		1,153,832			87,001

Commitments and Contingencies		-			-

Shareholders’ Equity
Class A Common stock, $0.001 par value; 30,000,000 shares authorized, 29,995,000 shares issued and outstanding		29,995			29,995
Additional paid-in capital		243,530			160,230
Accumulated deficit		(427,527	)		(276,332	)
Accumulated other comprehensive loss		(739	)		-
Total Equity		(154,741	)		(86,107	)
Total Liabilities and Shareholders’ Equity	$	999,091		$	894

The accompanying notes are an integral part of these financial statements

ANTIAGING QUANTUM LIVING INC (FKA. ACHISON INC)

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(Unaudited)

	2023			2022			2023			2022
	Three Months Ended						Nine Months Ended
	December 31,			December 31,			December 31,			December 31,
	2023			2022			2023			2022
Revenues, net	$	6,299		$	4,000		$	7,499		$	12,400
Cost of revenues		760			-			760			-
Gross profit		5,539			4,000			6,739			12,400

Operating expenses
Selling and marketing expense		10,687			-			10,687			-
General and administrative expenses		91,945			10,772			147,251			41,797
Total Operating expenses		102,632			10,772			157,938			41,797

Loss from operations		(97,093	)		(6,772	)		(151,199	)		(29,397	)

Other income (expense)
Other income, net		2			-			2			-
Interest income		1			-			1			-
Total other income, net		3			-			3			-

Loss before income tax		(97,090	)		(6,772	)		(151,196	)		(29,397	)
Income tax expense		-			-			-			-

Net loss		(97,090	)		(6,772	)		(151,196	)		(29,397	)

Weighted average shares outstanding
Basic		29,995,000			29,995,000			29,995,000			29,995,000
Diluted		29,995,000			29,995,000			29,995,000			29,995,000

Loss per share
Basic		-			-			(0.01	)		-
Diluted		-			-			(0.01	)		-

Other comprehensive income (loss):
Net loss		(97,090	)		(6,772	)		(151,196	)		(29,397	)
Other comprehensive loss		-			-
Foreign currency translation loss		(739)			-			(739)			-
Total comprehensive loss		(97,829	)		(6,772	)		(151,935	)		(29,397	)

The accompanying notes are an integral part of these financial statements

ANTIAGING QUANTUM LIVING INC (FKA. ACHISON INC)

STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

(Unaudited)

	Shares		Amount		Capital		Reserve		Deficit			Income			Total
	Class A Common Stock				Additional							Accumulated other
	Number of				Paid-in		Statutory		Accumulated			Comprehensive
	Shares		Amount		Capital		Reserve		Deficit			Income			Total
Balance at March 31, 2023		29,995,000	$	29,995		160,230	$	-	$	(276,332	)	$	-		$	(86,107	)
Shareholder loan cancellation		-		-		83,300		-		-			-			83,300
Net loss		-		-		-		-		(29,727	)		-			(29,727	)
Balance at June 30, 2023		29,995,000		29,995		243,530		-		(306,059	)		-			(32,534	)
Net loss		-		-		-		-		(24,378	)		-			(24,378	)
Balance at September 30, 2023		29,995,000		29,995		243,530		-		(330,437	)		-			(56,912	)
Net loss		-		-		-		-		(97,090	)		-			(97,090	)
Foreign currency translation adjustment		-		-		-		-		-			(739	)		(739	)
Balance at December 31, 2023		29,995,000		29,995		243,530		-		(427,527	)		(739	)		(154,741	)

Balance at March 31, 2022		29,995,000	$	29,995	$	160,230	$	-	$	(239,702	)	$	-		$	(49,477	)
Net loss		-		-		-		-		(21,105	)		-			(21,105	)
Balance at June 30, 2022		29,995,000		29,995		160,230		-		(260,807	)		-			(70,582	)
Net loss		-		-		-		-		(1,520	)		-			(1,520	)
Balance at September 30, 2022		29,995,000		29,995		160,230		-		(262,327	)		-			(72,102	)
Net loss		-		-		-		-		(6,772	)		-			(6,772	)
Balance at December 31, 2022		29,995,000		29,995		160,230		-		(269,099	)		-			(78,874	)

The accompanying notes are an integral part of these financial statements

ANTIAGING QUANTUM LIVING INC (FKA. ACHISON INC)

UNAUDITED CONDENSED STATEMENTS OF CASH FLOWS

	2023			2022
	Nine Months Ended
	December 31,			December 31,
	2023			2022
Cash flows from operating activities
Net loss	$	(151,196	)	$	(29,397	)
Depreciation		236			236
Amortization of operating lease ROU assets		50,550			-
Changes in assets and liabilities
Increase in advances to suppliers		(27,554	)		-
Increase in prepaid expenses		(28,423	)		(508	)
Increase in other current assets		(34,189	)		-
Increase in accrued and other liabilities		15,339			-
Decrease in account payable		18,098			600
Increase in other payable		2,995			-
Decrease in contract liability		(2,800	)		(1,600	)
Decrease in operating lease liabilities		(357,459	)		-
Net cash used in operating activities		(514,402	)		(30,669	)

Cash flows from investing activities
Purchase of fixed assets		(153,400	)		-
Net cash used in investing activities		(153,400	)		-

Cash flows from financing activities
Proceeds from loans payables		423,333			-
Proceeds from shareholder loan		369,073			17,300
Net cash used in financing activities		792,406			17,300

Net decrease of cash and cash equivalents		124,604			(13,369	)

Effect of foreign currency translation on cash and cash equivalents		690			-
Cash and cash equivalents, beginning balance		354			14,269
Cash and cash equivalents, ending balance	$	128,448		$	900

Supplementary cash flow information:
Interest paid	$	-		$	-
Income taxes paid	$	86		$	-

Non-cash financing and investing activities:
Related party debt forgiven as additional paid-in capital	$	83,300		$	-
Recognized ROU assets through lease liabilities	$	671,570		$	-

The accompanying notes are an integral part of these financial statements

ANTIAGING QUANTUM LIVING INC (FKA. ACHISON INC)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES

Antiaging Quantum Living Inc. (FKA: Achison Inc.) (the “Company”, “us”, “we” or “our”) was incorporated under the laws of the State of New York on December 29, 2014.

On July 1, 2019, Lansdale Inc, the principal stockholder of the Company (“Seller”) an entity controlled by the Company’s former President, Mr. Wanjun Xie, entered into a Stock Purchase Agreement (the “Agreement”) with Dazhong 368 Inc, (the “Buyer”), pursuant to which, a total of 9,000,000 shares of Class A common stock of the Company were transferred to the Buyer, representing approximately 90% of the Company’s issued and outstanding shares of Class A common stock, resulting in a change of the control of the Company. Mr. Dingshan Zhang was appointed as the President and CEO of the Company at the same date.

On April 10, 2023, Mr. Barry Wan acquired control of 29,215,000 restricted shares of common stock (the “Purchased Shares”) of the Company, representing approximately 97% of the Company’s total issued and outstanding common stock (the “Common Stock”) from Dazhong 368 Inc and Sophia 33 Inc, two New York corporations controlled by the Company’s then President, Chief Executive Officer and sole director, Dingshan Zhang (the former President) pursuant to the terms of a Stock Purchase Agreement by and among the parties thereto (the “Stock Purchase Agreement”). Pursuant to the Stock Purchase Agreement (“SPA”), Mr. Wan paid an aggregate purchase price of four hundred thousand dollars ($400,000.00) to Mr. Zhang in exchange for the Purchased Shares. The foregoing transaction resulted in a change of control of the Company, with Mr. Wan acquiring 97% of the Company’s outstanding Common Stock held through New Lite Ventures LLC, a New York LLC. Both before and after the transactions, the Company had 29,995,000 shares of its common stock outstanding.

In connection with the transaction, on April 10, 2023, Mr. Dingshan Zhang resigned from all positions he held with the Company. On April 10, 2023, Ms. Jing Wan was appointed by our majority shareholder as our Chief Executive Officer, Chief Financial Officer, President and Director. On June 16, 2023, Mr. Barry Wan consented to act as the new CEO and CFO after Ms. Jing Wan resigned. The Company was renamed as Antiaging Quantum Living Inc on June 14, 2023 by the new management. The Company is an investment holding company; its primary business operations are conducted through its subsidiaries as described below.

AAQL Inc. (“BVI Holding”) was incorporated under the Laws of the British Virgin Islands to function as a holding company responsible for managing all business operations outside of the United States.

AAQL HK Limited (“Hong Kong Holding”) was incorporated under the Laws of Hong Kong as a wholly-owned subsidiary of the BVI Holding. Hong Kong Holding’s primary role is to act as a holding company overseeing business activities exclusively within the Asia-Pacific markets.

Antiaging Doctor Hangzhou Holding LTD (“Dao Ling Doctor Hangzhou”) was incorporated as a wholly-owned subsidiary of Hong Kong Holding on November 13, 2023 under the laws of the People’s Republic of China, with its principal place of business situated in Xiaoshan District, Hangzhou, Zhejiang Province. Its primary business is to provide development, operation, and management services to domestic e-commerce platform companies, offering personalized marketing plans, promotional strategies, and charging brand usage fees for the “Dao Ling Doctor” brand.

Dao Ling Doctor (Zhejiang) Health Management Limited (“Dao Ling Doctor Zhejiang”) was incorporated as a wholly-owned subsidiary of Dao Ling Doctor Hangzhou on November 30, 2023 under the laws of the People’s Republic of China, with its principal place of business situated in Hangzhou, Zhejiang Province. Its primary business involves providing professional technical development and maintenance services to distributors of the “Dao Ling Doctor” brand, and collecting technical service fees.

Dao Ling Doctor (Huzhou) Health Management Limited (“Dao Ling Doctor Huzhou”) was incorporated as a wholly-owned subsidiary of Dao Ling Doctor Hangzhou on December 6, 2023 under the laws of the People’s Republic of China, with its principal place of business situated in Huzhou, Zhejiang Province. Its primary business involves providing health consulting services (excluding diagnosis and treatment services), network and information security software development and big data services, and other services.

Antiaging Quantum Living Inc. and its subsidiaries are collectively referred to as the “Company”.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and include the assets, liabilities, revenues, expenses and cash flows of all subsidiaries. All significant inter-company transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.

In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. However, the results of operations included in such financial statements may not necessary be indicative of annual results.

The Company uses the same accounting policies in preparing quarterly and annual financial statements. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2023 filed with the Securities and Exchange Commission (“SEC”) on July 14, 2023 (“2023 Form 10-K.”)

Use of Estimates

The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (the “SEC”).

The preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and footnotes thereto. Actual results may differ from those estimates and assumptions.

Functional and presentation currency

The functional currency of the Company is the currency of the primary economic environment in which the Company operates which is Chinese Yuan (“RMB”). The RMB is not freely convertible into the US dollar and may be subject to PRC currency restrictions for payments, including the distributions of dividends or retained earnings to the Company by its subsidiaries or its variable interest entities.

Transactions in currencies other than the entity’s functional currency are recorded at the rates of exchange prevailing on the date of the transaction. At the end of each reporting period, monetary items denominated in foreign currencies are translated at the rates prevailing at the end of the reporting periods. Exchange differences arising on the settlement of monetary items and on translation of monetary items at period-end are included in income statement of the period.

For the purpose of presenting these financial statements, the Company’s assets and liabilities are expressed in US$ at the exchange rate on the balance sheet date, stockholder’s equity accounts are translated at historical rates, and income and expense items are translated at the weighted average exchange rate during the period. The resulting translation adjustments are reported under accumulated other comprehensive income (loss) in the stockholder’s equity (deficits) section of the balance sheets.

Exchange rate used for the translation as follows:

SCHEDULE OF EXCHANGE RATE

US$ to RMB	Period End		Average
December 31, 2023		7.0786		7.1512
March 31, 2023		6.8691		-
December 31, 2022		6.8979		6.8562

Cash and Cash Equivalents

Cash and cash equivalents include cash in banks, bank deposits, and highly liquid investments with maturities of three months or less at the date of origination.

Advances to Suppliers

The Company occasionally makes advances to suppliers to secure future deliveries of goods or services. These advances are recorded as assets on the balance sheet and are recognized as inventory when the related goods are received or as expenses when the related services are received. These advances primarily relate to the purchase of inventory goods to be sold.

The Company periodically reviews the recoverability of advances to suppliers and establishes allowances for potential losses when necessary.

Property and Equipment

Property and equipment are carried at cost net of accumulated depreciation. Expenditures that improve the functionality of the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset.

Property and equipment are depreciated on a straight-line basis over the following periods:

Leasehold improvements		2 years
Office furniture

Impairment of Long-Lived Assets

The Company has adopted Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment (“ASC 360-10”). ASC 360-10 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve breakeven operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell. Impairment loss on property and equipment was $nil and $nil for the nine months ended December 31, 2023 and 2022, respectively.

Customer Advances

The Company records customer advances as liabilities when consideration is received in advance of the transfer of goods. These advances are recognized as revenue when the performance obligations associated with the advance are satisfied. These advances relate to the advance payment for orders of goods placed by the customers.

Lease

The Company adopted FASB Accounting Standards Codification, Topic 842, Leases (“ASC 842”) using the modified retrospective approach, electing the practical expedient that allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019.

The new leasing standard requires recognition of leases on the balance sheets as right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the Company’s right to use underlying assets for the lease terms and lease liabilities represent the Company’s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. The Company’s future minimum based payments used to determine the Company’s lease liabilities mainly include minimum based rent payments. As most of the Company’s leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company does not recognize any leases with an initial term of 12 months or less on the balance sheets.

Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which the variable lease payments are based occur.

Revenue Recognition

Revenue is recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. The Company determines revenue recognition by applying the following steps: 1) identification of the contract, or contracts, with a customer; 2) identification of the performance obligations in the contract; 3) determination of the transaction price; 4) allocation of the transaction price to the performance obligations in the contract; and 5) recognition of revenue when, or as, we satisfy a performance obligation.

Online advertising

The Company operates an online advertising platform that connects advertisers with publishers to display digital advertisements.

For the Company, revenue recognition occurs upon the following events: when a customer places an order, payment is received, and the advertisement is delivered and viewable to the end-user with no other terms and conditions.

Sales of goods

The Company operates a mobile application (“App”) through which it sells health and beauty products to customers.

For the Company, revenue recognition occurs upon the following events: when a customer places an order, payment is received, and the goods are delivered to or drop-shipped to and accepted by the customer. Provisions are made for estimated sales returns based on historical return rates and experience which are immaterial. The Company may record contract liabilities, such as customer advances, when payments are received from customers prior to delivery or acceptance of goods by customers.

Selling, General and Administrative Expenses

Selling, general, and administrative expenses primarily consist of costs related to sales and marketing activities, administrative functions, and certain start-up costs.

Selling expenses include, but are not limited to, sales commissions, advertising costs, shipping and handling expenses, and costs associated with trade shows and promotional events. General and administrative expenses encompass salaries and benefits of employees not directly involved in production, rent, utilities, office supplies, legal and professional fees, other overhead costs, and certain start-up costs.

Start-up costs represent expenses associated with the establishment of new operations, including activities such as market research, product development, and initial marketing efforts.

The Company recognizes these expenses as incurred, consistently matching with the revenues generated.

Income Taxes

The Company records income tax expense using the asset-and-liability method of accounting for deferred income taxes. Under this method, deferred taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Deferred tax assets are reduced by a valuation allowance if, based on available evidence, it is more likely than not that the deferred tax assets will not be realized.

When tax returns are filed, it is likely some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more-likely-than-not the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are classified in general and administrative expenses in the statements of operations.

Earnings Per Share

The Company computes basic and diluted earnings per share amounts in accordance with ASC Topic 260, Earnings per Share. Basic earnings per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

As of December 31, 2023 and March 31, 2023, the Company does not have any potentially dilutive instrument.

Contingencies

Certain conditions may exist as of the date the financial statements are issued, which could result in a loss to the Company which will be resolved when one or more future events occur or fail to occur. The Company’s management assesses such contingent liabilities, and such assessment inherently involves judgment. In assessing loss contingencies arising from legal proceedings pending against the Company or unasserted claims that may rise from such proceedings, the Company’s management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

If the assessment of a contingency indicates it is probable a material loss will be incurred and the amount of the loss can be reasonably estimated, then the estimated loss is accrued in the Company’s financial statements. If the assessment indicates a material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed.

Fair Value Measurements

Fair value accounting establishes a framework for measuring fair value and expands disclosure about fair value measurements. Fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. This framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows:

	●	Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

	●	Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments.

	●	Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

The Company’s financial instruments consisted of cash, accounts payable, contract liabilities and loan from shareholders. The estimated fair value of those balances approximates the carrying amount due to the short maturity of these instruments.

Credit Losses on Financial Instruments

The Company recognizes credit losses on financial instruments in accordance with Accounting Standards Codification (ASC) Topic 326, Financial Instruments – Credit Losses. The Company uses the Current Expected Credit Losses (CECL) model to estimate credit losses on financial assets measured at amortized cost, as well as certain off-balance sheet credit exposures.

Under the CECL model, the estimation of credit losses involves significant judgment and estimation uncertainty. Management exercises its judgment based on historical loss experience, current economic conditions, and reasonable and supportable forecasts. Changes in these factors could have a material impact on the estimated credit losses.

As of December 31, 2023, the Company does not have any financial instruments subject to credit loss evaluation.

Income Taxes

The Company accounts for income taxes using an asset and liability approach which allows for the recognition and measurement of deferred tax assets based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will either expire before the Company is able to realize their benefits, or that future deductibility is uncertain.

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred.

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, (Topic 326), Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments which amends the current accounting guidance and requires the use of the new forward-looking “expected loss” model, rather than the “incurred loss” model, which requires all expected losses to be determined based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10 to postpone the effective date of ASU No. 2016-13 for public business entities eligible to be smaller reporting companies (SRCs) as defined by the SEC. ASU No. 2016-13 is effective for SRCs for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted ASU 2016-13 on its financial position and results of operations as of April 1, 2023, with no material impact.

There were other updates recently issued. The management does not believe that other than the disclosed above, accounting pronouncements the recently issued but not yet adopted will have a material impact on its financial position results of operations or cash flows.

NOTE 3 – GOING CONCERN

The Company’s financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. The Company had an accumulated deficit of $427,527 as of December 31, 2023 and negative working capital of $57,295. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

Management’s plan to alleviate the substantial doubt about the Company’s ability to continue as a going concern include attempting to improve its business profitability, its ability to generate sufficient cash flow from its operations to meet its operating needs on a timely basis, obtain additional working capital funds from the majority shareholder and President of the Company to eliminate inefficiencies in order to meet its anticipated cash requirements. However, there can be no assurance that these plans and arrangements will be sufficient to fund the Company’s ongoing capital expenditures and other requirements.

The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

NOTE 4 – PROPERTY AND EQUIPMENT

Property and equipment, net comprised of the following:

SCHEDULE OF PROPERTY AND EQUIPMENT

	December 31, 2023			March 31, 2022
At Cost:
Leasehold improvements in progress		154,873			-
Office furniture		950			950
Total cost		155,823			950
Less: Accumulated depreciation		(646	)		(410	)
Total, net		155,277			540

Depreciation expenses was $236 and $236 for the nine months ended December 31, 2023 and 2022, respectively.

NOTE 5 – LOANS PAYABLE

The Company has outstanding loans payable to unrelated third parties in the amount of $427,675 and $nil as of December 31, 2023 and March 31, 2023, respectively. These loans are unsecured, non-interest-bearing, with a maturity date of October 19, 2026.

NOTE 6 – RELATED PARTY TRANSACTIONS

Loan from shareholders

In August 2019, the Company borrowed $71,000 from the former President of the Company, Mr. Dingshan Zhang, which bears no interest with a maturity in December 2021. During the year ended March 31, 2022, the Company repaid $17,000 to Mr. Zhang. In May 2021 the Company borrowed an additional $5,000 from Mr. Zhang. On December 29, 2021, the Company and Mr. Zhang verbally amended the loan agreement and extended the maturity date to December 31, 2023. During the year ended March 31, 2023, the Company received an additional loan in the total amount of $24,300 from, Mr. Zhang. Upon consummation of the change of control which resulted from that certain SPA entered into on April 10, 2023, the balance of the $83,300 shareholder loan was waived by Mr. Zhang in its entirety, which was recognized as an equity transaction with the shareholder.

During the nine months ended December 31, 2023, the Company received advances in the total amount of $371,369 from Mr. Wan, our President for working capital purpose. The loan is unsecured, non-interest-bearing and due on demand. The amount due to Mr. Wan was $371,369 and $nil as of December 31, 2023 and March 31, 2023.

NOTE 7 – CONTRACT LIABILITIES

Contract liabilities represent payments received in advance of performance under the contract for the unsatisfied performance obligation and are realized when the associated revenue is recognized under the advertising contracts. As of December 31, 2023 and March 31, 2023, contract liabilities were $nil and $2,800, respectively.

NOTE 8 – INCOME TAX

The Company has not recognized an income tax benefit for its operating losses generated based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the period presented is offset by a valuation allowance established against deferred tax assets arising from the net operating losses, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not.

United States

Net operation losses (“NOLs”) can carry forward indefinitely up to offset 80% of taxable income after CARES Act effect on December 31, 2017. As of December 31, 2023 and March 31, 2023, deferred tax assets resulted from NOLs of approximately $92,000 and $69,000, respectively. The deferred tax asset has been fully reserved for valuation allowance as the Company believes they will most-likely-than-not realize the benefits.

Hong Kong

Companies incorporated in Hong Kong are subject to Hong Kong Profits Tax on the taxable income as reported in its statutory financial statements adjusted in accordance with relevant Hong Kong tax laws. The applicable tax rate is 16.5% on its taxable income generated from operations in Hong Kong. The Company did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earned in Hong Kong since inception. Additionally, payments of dividends by the subsidiary incorporated in Hong Kong to the Company are not subject to any Hong Kong withholding tax.

PRC

Effective on January 1, 2008, the PRC Enterprise Income Tax Law, EIT Law, and Implementing Rules impose a unified enterprise income tax rate of 25% on all domestic-invested enterprises and foreign investment enterprises in PRC, unless they qualify under certain limited exceptions. As such, starting from January 1, 2008, the Company’s subsidiaries in PRC are subject to an enterprise income tax rate of 25%. NOLs can typically carried forward for a certain number of years (usually five years) to offset against future taxable income. The deferred tax asset has been fully reserved for valuation allowance as the Company believes they will most-likely-than-not realize the benefits.

The following table summarizes the taxable income (loss) before income taxes by jurisdiction:

	2023			2022
	Nine months Ended December 31,
	2023			2022
United States	$	(79,382	)	$	(29,397	)
Hong Kong		-			-
China		(71,814	)		-
Total	$	(151,196	)	$	(29,397	)

The following table summarizes a reconciliation of income tax expense for operations, calculated at the U.S. statutory federal income tax rate of 21% to total income tax expense (benefit):

	2023			2022
	Nine months Ended December 31,
	2023			2022
Income tax expense at federal statutory rate		21.0	%		21.0	%
Increases/(decreases) due to:
Foreign tax rate differential		-	%		-	%
Change in valuation allowance		(21.0	)%		(21.0	)%
Effective tax rate		-	%		-	%

NOTE 9 – SHAREHOLDERS’ EQUITY

The Company is authorized to issued 30,000,000 shares of Class A common stock.

On August 19, 2019, the Company amended its article with New York State to increase the authorized Class A common shares with a par value of $0.001 to 30,000,000 shares.

On October 11, 2021, the Company amended its article with New York State to change the authorized Class A common shares with a par value of $0.001 to 100,000,000 shares; and to increase the authorized preferred shares with par value $0.001 to 20,000,000 shares.

On March 28, 2023, the Company amended its article with New York State to change the authorized common shares with a par value of $0.001 to 30,000,000 shares, no preferred shares.

During the nine months ended December 31, 2023, a shareholder loan in the amount of $83,300 was forgiven by our former President and recorded as additional paid-in capital.

NOTE 10 – LEASES

The Company has two operating leases for its office space.

Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to calculate present value is incremental borrowing rate or, if available, the rate implicit in the lease. The Company determines the incremental borrowing rate for each lease based primarily on its lease term in PRC which is approximately 4.75%.

Operating lease expenses were $53,022 and $nil for the nine months ended December 31, 2023 and 2022, respectively.

The components of lease expense and supplemental cash flow information related to leases for the period are as follows:

	Nine months Ended December 31,
	2023			2023
Lease cost
Operating lease cost	$	53,022		$	-

Other Information
Cash paid for amounts included in the measurement of lease liabilities	$	359,930		$	-
Weighted average remaining lease term – operating leases (in years)		2			-
Average discount rate – operating lease		4.75	%		-	%

The supplemental balance sheet information related to leases is as follows:

	December 31, 2023		March 31, 2023
Operating leases
Right-of-use assets	$	627,389	$	-
Operating lease liabilities	$	688,702	$	-

The undiscounted future minimum lease payment schedule as follows:


For the year ending March 31,
2024 (3 months remaining)	-
2025	332,739
Thereafter	-
Total undiscounted lease payments	332,739
Less: interest	(15,406	)
Total lease liabilities	317,333

NOTE 11 – SUBSEQUENT EVENTS

The Company evaluated all events or transactions that occurred after December 31, 2023 through the date the financial statements were issued. During the period, the Company did not have any material recognizable subsequent events required to be disclosed or adjusted as of and for the nine months ended December 31, 2023.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Quarterly Report on Form 10-Q contains forward-looking statements, particularly those identified with the words, “anticipates,” “believes,” “expects,” “plans,” “intends,” “objectives,” and similar expressions. These statements reflect management’s best judgment based on factors known at the time of such statements. The reader may find discussions containing such forward-looking statements in the material set forth under “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” generally, and specifically therein under the captions “Liquidity and Capital Resources” as well as elsewhere in this Quarterly Report on Form 10-Q. Actual events or results may differ materially from those discussed herein. The forward-looking statements specified in the following information have been compiled by our management on the basis of assumptions made by management and considered by management to be reasonable. Our future operating results, however, are impossible to predict and no representation, guarantee, or warranty is to be inferred from those forward-looking statements. The assumptions used for purposes of the forward-looking statements specified in the following information represent estimates of future events and are subject to uncertainty as to possible changes in economic, legislative, industry, and other circumstances. As a result, the identification and interpretation of data and other information and their use in developing and selecting assumptions from and among reasonable alternatives require the exercise of judgment. To the extent that the assumed events do not occur, the outcome may vary substantially from anticipated or projected results, and, accordingly, no opinion is expressed on the achievability of those forward-looking statements. No assurance can be given that any of the assumptions relating to the forward-looking statements specified in the following information are accurate, and we assume no obligation to update any such forward-looking statements.

Overview

Antiaging Quantum Living Inc. (FKA: Achison Inc.) (the “Company”, “us”, “we” or “our”) was incorporated under the laws of the State of New York on December 29, 2014.

On July 1, 2019, Lansdale Inc., the principal stockholder of the Company (“Seller”) and an entity controlled by the Company’s former President, Mr. Wanjun Xie, entered into a Stock Purchase Agreement (the “Agreement”) with Dazhong 368 Inc., (the “Buyer”), pursuant to which, a total of 9,000,000 shares of Class A common stock of the Company were transferred to the Buyer, representing approximately 90% of the Company’s issued and outstanding shares of Class A common stock, resulting in a change of the control of the Company. Mr. Dingshan Zhang was appointed as the President and CEO of the Company on the same date.

On April 10, 2023, Mr. Barry Wan acquired control of 29,215,000 restricted shares of Class A common stock (the “Purchased Shares”) of the Company, representing approximately 97% of the Company’s total issued and outstanding common stock from Dazhong 368 Inc and Sophia 33 Inc, two New York corporations controlled by the Company’s then President, Chief Executive Officer and sole director, Dingshan Zhang (the former President) pursuant to the terms of a Stock Purchase Agreement by and among the parties thereto (the “Stock Purchase Agreement”). Pursuant to the Stock Purchase Agreement, Mr. Wan paid an aggregate purchase price of four hundred thousand dollars ($400,000.00) to Mr. Zhang in exchange for the purchased shares. The foregoing transaction resulted in a change of control of the Company, with Mr. Wan acquiring 97% of the Company’s outstanding Class A common stock held through New Lite Ventures LLC, a New York LLC. Both before and after the transactions, the Company had 29,995,000 shares of its Class A common stock outstanding.

In connection with the transaction, on April 10, 2023, Mr. Dingshan Zhang resigned from all positions he held with the Company. On April 10, 2023, Ms. Jing Wan was appointed by our majority shareholder as our Chief Executive Officer, Chief Financial Officer, President and Director. On June 16, 2023, Mr. Barry Wan consented to act as the new Chief Executive Officer and Chief Financial Officer after Ms. Jing Wan resigned. The Company changed its name to Antiaging Quantum Living Inc. on June 14, 2023.

The change in control with respect to the Company was effectuated to better reflect its new business direction, with the intention of acquiring businesses involved in healthcare management and insurance services.

In line with this expansion, the Company established AAQL Inc. AAQL HK Limited Dao Ling Doctor Hangzhou, Dao Ling Doctor Zhejiang, and Dao Ling Doctor Huzhou entities.

Results of Operation for the three months ended December 31, 2023 and 2022

	2023			2022			$ Changed			% Changed
Revenue		6,299			4,000			2,299			57.48	%
Cost of revenues		760			0			760			100.00	%
General and administrative expenses		102,632			10,772			91,860			852.77	%
Other income (loss)		3			0			3			100.00	%
Loss from operations		(97,090	)		(6,772	)		(90,318	)		1333.70	%
Net loss		(97,090	)		(6,772	)		(90,318	)		1333.70	%

During the three months ended December 31, 2023 and 2022, the Company generated revenue in the amount of $6,299 and $4,000, respectively. During the three months ended December 31, 2023 and 2022, the Company incurred operating expenses of $102,632 and $10,772, respectively. The Company commenced selling of health and beauty products through mobile app in the quarter ending December 31, 2023. The increase in revenues and costs are related to the sales of health and beauty products. The increase in operating expenses was mainly due to the increase in rental expenses and employee wages and benefits, which are related to the new entities established as part of the Company’s initiative for business expansion. The Company also incurred start-up costs such as cloud hosting expenses, development and maintenance costs in pursuit of its business plan.

For the three months ended December 31, 2023, our net loss was $97,090 comparing to a net loss of $6,772 for the three months ended December 31, 2022. The increase in net loss is mainly due to the increased operating expenses.

Results of Operation for the nine months ended December 31, 2023 and 2022

	2023			2022			$ Changed			% Changed
Revenue		7,499			12,400			(4,901	)		(39.52	)%
Cost of revenues		760			0			760			100.00	%
General and administrative expenses		147,251			41,797			105,454			252.30	%
Other income (loss)		3			0			3			100.00	%
Loss from operations		(151,199	)		(29,397	)		(121,802	)		414.33	%
Net loss		(151,196	)		(29,397	)		(121,799	)		414.32	%

During the nine months ended December 31, 2023 and 2022, the Company generated revenue in the amount of $7,499 and $12,400, respectively. During the nine months ended December 31, 2023 and 2022, the Company incurred operating expenses of $147,251 and $41,797, respectively. The increase in operating expenses was mainly due to the increase in charitable donation expense of $10,000, rental expenses and employee wages and benefits, and professional fees. To align with the business direction, the Company increased professional fees and other services as required. Moreover, as an act of goodwill and a display of philanthropy, the Company made a charitable donation of $10,000.

For the nine months ended December 31, 2023, our net loss was $151,196 comparing to a net loss of $29,397 for the nine months ended September 30, 2022. The increase in net loss is mainly due to the increased operating expenses.

Equity and Capital Resources

As of December 31, 2023, we had an accumulated deficit of $427,527. As of December 31, 2023, we had cash of $125,648 and negative working capital of $542,859, compared to cash of $354 and a negative working capital of $86,647 as of March 31, 2023.

The increase in the working capital was primarily due to advances from related party, proceeds from loans payable, increase of accounts payables and customer advances, and the loan forgiveness by the former President which was partially offset by cash used to pay for operating expenses.

The accounts payable increase as a result of unpaid service fees incurred, while customer advances increased as a result of payments received from customers who placed order of goods through its mobile application.

We had Cash and cash equivalent of approximately $125,648 at December 31, 2023, and the Company also do not have any bank loans; Our liabilities are mainly borrowed by the Company’s shareholders and do not require us to return them at this time. Shareholders will continue to invest if necessary. Now, the company is operating normally, and we will make some efforts on our expense control in the near future.

Going Concern Assessment

The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern. These adverse conditions are negative financial trends, specifically cash outflow from operating activities, operating losses, accumulated deficit and other adverse key financial ratios.

Management’s plan to alleviate the substantial doubt about the Company’s ability to continue as a going concern include attempts to consummate a business combination and to generate sufficient cash flow from its operations to meet its operating needs on a timely basis; as well as to obtain additional working capital funds as loans from the majority shareholder and the President of the Company.

The unaudited condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Critical Accounting Policies

The financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires making estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis of making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

The critical accounting policies are discussed in further detail in the notes to the unaudited financial statements appearing elsewhere in this 10-Q report. Management believes that the application of these policies on a consistent basis enables us to provide useful and reliable financial information about our operating results and financial condition

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company” we are not required to provide this information under this item pursuant to Regulation S-K.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are designed with an objective of ensuring that information required to be disclosed in our periodic reports filed with the Securities and Exchange Commission, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission. Disclosure controls are also designed with an objective of ensuring that such information is accumulated and communicated to our management, including our chief executive officer, in order to allow timely consideration regarding required disclosures.

The evaluation of our disclosure controls by our principal executive officer included a review of the controls’ objectives and design, the operation of the controls, and the effect of the controls on the information presented in this Annual Report. Based on our management’s evaluation, our Chief Executive Officer, have concluded that as of such date, our disclosure controls were not, in design and operation, effective at a reasonable assurance level due to the material weaknesses in internal control over financial reporting. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Also, projections of any evaluation of the disclosure controls and procedures to future periods are subject to the risk that the disclosure controls and procedures may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that there were material weakness in our internal controls over Financial reporting as of December 31, 2023 and they were therefore not as effective as they could be to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. The material weakness in our controls and procedure were lack of US GAAP knowledge and segregation duties. Management does not believe that any of these material weaknesses materially affected the results and accuracy of its financial statements. However, in view of this discovery of such weaknesses, management has begun a review to improve them.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or Rule 15d-15 under the Exchange Act that occurred during the quarter ended December 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

None

Item 1A. Risk Factors.

As a “smaller reporting company”, we are not required to provide this information under this item pursuant to Regulation S-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3. Defaults Upon Senior Securities

None

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None

Item 6. Exhibits

Exhibit Number		Description of Exhibit
3.1*		Articles of Incorporation (filed as exhibit to the Form S-1 filed with the SEC on May 2, 2016)

3.2*		By-laws (filed as an Exhibit to Form S-1 filed with the SEC on May 2, 2016)

31.1**		Certification of Principal Executive Officer pursuant to the Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2**		Certification of Principal Financial Officer pursuant to the Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act.

32.1**		Certification of Principal Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Principal Financial Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		Inline XBRL Instance Document

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Incorporated by reference to the Company’s Registration Statement on Form S-1 as filed with the SEC on May 2, 2016.

** Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ANTIAGING QUANTUM LIVING INC

Date: February 14, 2024	/s/ Barry Wan
	Barry Wan, Chief Executive Officer

Date: February 14, 2024	/s/ Barry Wan
	Barry Wan, Chief Financial Officer

Antiaging Quantum Living Inc. 10-Q